CSF2 and neuroblastoma: In 2017, Dinutuximab β (ch14.18/CHO) was approved by the European Commission for the treatment of high-risk neuroblastoma patients in Europe, whereas Naxitamab (a humanized mAb Hu3F8) in combination with GM-CSF was approved by the FDA in 2020 for the treatment of relapsed high-risk neuroblastoma patients or those who show refractory disease in the bone or bone marrow (181).